P-21 Activated Kinases in Liver Disorders
, Hanzhi Xu 1,2,†, Kai Wang 1,3,*, Fengqiang Gao 1,2, Xiao Xu 2,3,4 and Hong He 5,*Round 1
Reviewer 1 Report
The current review reads well. Several new Pak inhibitors are shown in literature and this need to be updated
Rest looks fine
Author Response
Please refer to the attached " Address to reviewers' comments"
Author Response File: 
Author Response.pdf
Reviewer 2 Report
An excellent and comprehensive review, no recommendations
Author Response
Please see the attachment.
Author Response File: Author Response.pdf
Reviewer 3 Report
In the present review the authors try to provide an overview on current progress of P-21- activated kinases (PAKs) in liver diseases with especial focus on the HCC. However, there are many major issues that should be addressed:
1- The review is not well organized and need further arrangements, Example: the discussion section ?????
2- The Table 1 is confusing and need to be more organized. You could arrange the data as follow: Type of PAKs, Liver disorders, Type of change (increase or decrease of the activity or expression, then the affected pathway.
3- Section 2 (Structure and Activation of PAKs) needs graphical illustration
4- The pathways affected by PAKs should be under specific heading with illustrating graph for better follow of the data
5- It is better to add additional sections to the review: One about the physiological role of PAKs (at least in the liver physiology) and another one for the transcriptional and translational regulation of PAKs.
6- Many abbreviations in the article without the full names
7- The word "Effects" in the subtitles (3. PAKs in liver cancer) should be replaced by (Roles)
Author Response
Please see the attachment.
Author Response File: Author Response.pdf
Round 2
Reviewer 3 Report
No comment
